Glenmark Pharmaceuticals Limited (NSE: GLENMARK, BSE: 532296) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹62,838 Cr, it ranks #167 by market cap among the 6,137 Indian listed companies on FinBizNet, and #9 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,166.60 (as of 25 Oct 2026), the share price is 14.6% below its 52-week high of ₹2,537.60 and 20.9% above its 52-week low of ₹1,792.60. The share price is up 16.2% over one year and down 1.2% over three months.
| Current Price | ₹2,166.60 |
|---|---|
| Market Cap | ₹62,838 Cr |
| NSE Symbol | GLENMARK |
| BSE Code | 532296 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 45.7 |
| Return on Equity | 14.07% |
| Return on Assets | 14.11% |
| 52-Week Range | ₹1,792.60 – ₹2,537.60 |
| 1-Year Price Change | +16.2% |
| 3-Month Price Change | -1.2% |
| Beta (1Y) | 0.39 |
| Dividend Yield | 0.23% |
| Headquarters | Mumbai, Maharashtra |
| Website | glenmarkpharma.com |
| Revenue | ₹4,018 Cr |
|---|---|
| Net Profit | ₹483 Cr |
| Net Margin | 12.0% |
| EPS (Basic) | ₹17.11 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for
1. Pharmaceuticals-This segment develops, manufactures, and markets pharmaceutical products. It provides active pharmaceutical ingredients in the therapeutic areas of alimentary track, anti-infective, anti-parasitic, cardiovascular, central nervous system, dermatological, genito-urinary, musculo-skeletal, respiratory, and others; and formulations in the therapeutic areas of dermatology, respiratory, cardiovascular, anti- diabetic, and oncology.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹62,838 Cr | 45.7 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Glenmark Pharmaceuticals Limited is trading at ₹2,166.60, with a market capitalisation of ₹62,838 Cr.
Glenmark Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Glenmark Pharmaceuticals Limited has a P/E of 45.7 and a return on equity of 14.07%.
Glenmark Pharmaceuticals Limited is listed on the NSE under the symbol GLENMARK and on the BSE under the scrip code 532296.
Glenmark Pharmaceuticals Limited's share price is up 16.2% over one year and down 1.2% over three months. Its 52-week range is ₹1,792.60 to ₹2,537.60.
In Q1 FY27, Glenmark Pharmaceuticals Limited reported revenue of ₹4,018 Cr and net profit of ₹483 Cr, with basic EPS of ₹17.11 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.